Prostate Tumor Antigen Discovery: Development of a Novel Genetic Approach
Abstract
Immunotherapy may provide an effective adjunct to current treatment modalities for prostate cancer. To achieve this goal, several fundamental immunologic questions need to be addressed. These include optimization of cellular immune responses to candidate tumor antigen and exploration of the extent to which HLA Class I and Class II diversity will restrict application of a candidate prostatic cancer vaccine. PSA was chosen as a candidate antigen for study and dendritic cells (DC) the vehicle for antigen delivery. DC armed with PSA generated predominately HLA Class II mediated CD4+ (helper) responses. However when combined with an anti-PSA monoclonal antibody, CD4+ as well as CDB+ T cell responses were generated. CDB+ T cell responses were at least in part restricted by PSA peptides known to bind the HLA-A*0201 allele. T cell clones were generated from peripheral blood from two patients with disease of the prostate (cancer, prostatitis) and HLA restriction studied. We identified peptide sequences in PSA that were presented by HLA-B*0702 to CD8+ T cells (previously unreported), and an HLA Class II allele (HLA DR*1501) restricted CD4+ T cell response. The result of these studies contribute to a rational basis for prostate cancer immunotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2000
- Accession Number
- ADB262442
Entities
People
- Dean L. Mann
- R. C. Malone
Organizations
- University of Maryland, Baltimore